Mevastatin

RTECS: EK7907100 Source/Host Chemicals: Synthetic. Appearance: White to light yellow powder. Solubility: Soluble in DMSO or ethanol (20mg/ml). Insoluble in water. Identity: Determined by 1H-NMR. InChi Key: AJLFOPYRIVGYMJ-INTXDZFKSA-N Smiles: [H][C@@]12C(C=C[C@H](C)[C@]2([H])CC[C@@]3([H])OC(C[C@@](O)([H])C3)=O)=CCC[C@@H]1OC([C@@H](C)CC)=O Mevastatin is an antibiotic that is a competitive HMG-CoA reductase inhibitor, thus suppressing Ras farnesylation. Mevastatin decreases cholesterol biosynthesis in vitro and in vivo. It induces apoptosis, arrests cancer cells in G1 phase and downregulates cdk 2, 4, and 6, cyclin D1 and E1, p21 and p27. Mevastatin also suppresses TNF-induced NF-kappaB activation and potentiates apoptosis in human myeloid leukemia cells. Mevastatin induced neurite outgrowth of neuroblastoma cells via activation of EGFR, ERK1/2 and Akt/PBK but also exerts a neurotoxic effect in cultured neurons in a heme-independent manner. Mevastatin also shows antileishmanial and antifungal activity. Has also anti-inflammatory effects potentially via up-regulation of heme oxygenase-1 (HO-1). Product References: [1] A. Endo, et al., FEBS Lett. 72, 323 (1976) , [2] R. Fears, et al., Atherosclerosis 35, 439 (1980) , [3] K. Keyomarsi, et al., Cancer Res. 51, 3602 (1991) , [4] A. Endo, J. Lipid Res. 33, 1569 (1992) , [5] S. Amin-Hanjani, et al, Stroke 32, 980 (2001) , [6] A. Wachtershauser, et al., Carcinogenesis 22, 1061 (2001) , [7] K.S. Ahn, et al., Biochem. Pharmacol. 75, 907 (2008) , [8] M.E. Evangelopoulos, et al., J. Neurosci. Res. 87, 2138 (2009) , [9] M. Kannan, et al., Neurobiol. Aging 31, 1543 (2010) , [10] N. Dinesh, et al., Parasitol. Res. 114, 3873 (2015) , [11] S. Javed, et at., Curr. Pharm. Biotechnol. 17, 291 (2016) , [12] Z. Lin, et al., Oncotarget 8, 17833 (2017) , [13] C.-C. Lin, et al., J. Clin. Med. 9, 226 (2020)